^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ifabotuzumab (KB004)

i
Other names: KB004 , KB-004
Company:
Humanigen, Olivia Newton-John Cancer Research Institute
Drug class:
EPH receptor inhibitor, EphA3 inhibitor
Related drugs:
3years
A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
P1, N=12, Completed, Olivia Newton-John Cancer Research Institute | Active, not recruiting --> Completed
Clinical • Trial completion
|
EPHA3 (EPH receptor A3)
|
ifabotuzumab (KB004)
over3years
A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Trial completion date: Apr 2021 --> Sep 2021
Clinical • Trial completion date
|
EPHA3 (EPH receptor A3)
|
ifabotuzumab (KB004)